Related Experiment Videos
Treatment of oligozoospermia with tamoxifen (open and controlled studies)
Abstract:
Open and double-blind therapeutic studies were carried out on the effects of tamoxifen in oligozoospermia. The examinations involved 74 patients. The first group (n = 20) received tamoxifen 20 mg/day; the second group (n = 54) got tamoxifen or placebo for 3 months. In the open study, tamoxifen treatment led to significant increases in the spermatozoa concentration and the total sperm count, but this could not be confirmed with the double-blind set-up.
Insights
Tamoxifen showed potential in improving sperm count in an open study for male infertility. However, these positive effects on sperm concentration and count were not confirmed in a subsequent double-blind trial.
Area of Science:
- Reproductive Endocrinology
- Andrology
- Clinical Pharmacology
Background:
- Oligozoospermia, characterized by low sperm count, is a significant cause of male infertility.
- Tamoxifen, a selective estrogen receptor modulator, has been investigated for its potential therapeutic effects in male reproductive disorders.
Purpose of the Study:
- To evaluate the efficacy of tamoxifen in treating oligozoospermia.
- To assess the impact of tamoxifen on sperm concentration and total sperm count in infertile men.
Main Methods:
- Conducted open and double-blind therapeutic studies involving 74 patients with oligozoospermia.
- Administered tamoxifen (20 mg/day) or placebo for 3 months in different study arms.
- Monitored spermatozoa concentration and total sperm count as primary outcome measures.
Main Results:
- The open study indicated a significant increase in spermatozoa concentration and total sperm count following tamoxifen treatment.
- The double-blind study failed to confirm these improvements, suggesting a potential placebo effect or lack of consistent efficacy.
Conclusions:
- Tamoxifen demonstrated a positive effect on sperm parameters in an open-label setting for oligozoospermia.
- The efficacy of tamoxifen in improving sperm concentration and count was not substantiated in a rigorous double-blind, placebo-controlled trial.